Friday, November 13, 2026

USD/EUR Bearish Momentum With A 2% Slide In The Last 21 Sessions

USD/EUR Bearish Momentum With A 2% Slide In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.95% for the last 21 sessions. At 20:10 EST on Wednesday, 5 April, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.103% up from its 52-week low and 12.526% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.26%, a negative 0.17%, and a positive 0.47%, respectively.

USD/EUR's highest amplitude of average volatility was 0.55% (last week), 0.53% (last month), and 0.47% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd forecast: euro faces challenges, but shows strength - 05 April 2023. According to DailyForex on Wednesday, 5 April, "However, the EUR/USD market is currently in an extreme high and it remains to be seen whether the gains will be sustained. "
  • Eur/usd forex signal: extremely bullish above 1.0935 - 04 April 2023. According to DailyForex on Tuesday, 4 April, "The main catalyst for the EUR/USD pair was the surprise decision by OPEC+ to slash oil production by more than 1 million barrels. ", "The EUR/USD pair also reacted to the latest European and US manufacturing PMI numbers. "
  • Eur/usd clings to mild gains at two-month high below 1.1000, US pmis, ADP employment data eyed. According to FXStreet on Wednesday, 5 April, "Not only the upbeat signal for the old continent but downbeat US data and the greenback's less acceptance among the key global trade players seem to keep the EUR/USD pair buyers hopeful.", "Looking forward, EUR/USD traders should pay attention to the final readings of the Germany and Eurozone PMIs for intermediate directions ahead of the US ISM Services PMI and ADP Employment Change for March. "
  • A higher eur/usd certainly looks the direction of travel for the rest of the year – ING. According to FXStreet on Tuesday, 4 April, "Overall, we suspect that the market will be reluctant to chase EUR/USD above 1.10 yet given concerns about the regional US banking system. ", "But a higher EUR/USD certainly looks the direction of travel for the rest of the year."
  • Eur/usd rises above 1.0900 on growing speculation for a fed pause. According to FXStreet on Tuesday, 4 April, "From a daily chart perspective, the EUR/USD triplet bottom remains in play, targeting 1.1000. ", "On Monday, the EUR/USD dipped and tested the 20-day EMA at 1.0788 before skyrocketing above 1.0900. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com